groups reported significantly higher levels of sexual arousal and lubrication than the placebo group.
Presentation Title: Effects of a topical alprostadil
cream on expression of c-fos and oxytocin like immunoreactivity in hypothalamus of female rats.
For a six-month period, subjects will apply either a dose of alprostadil
or a placebo prior to every sexual encounter.
in Topiglan is different from the active ingredients in the oral 'PDE-5 inhibitor' ED drugs," Mr.
ALISTA's active ingredient, alprostadil
, is a synthetic version of prostaglandin E1 (PGE1), a naturally occurring vasodilating agent.
Lu commented, "We are very encouraged by the results of this pilot study which suggest that alprostadil
combined with lidocaine and our NexACT(R) technology presents a significant development opportunity for an effective treatment for premature ejaculation.
Padma-Nathan will present the meta-analysis of the combined Alprox-TD(R) US Phase 2 clinical results, along with new data from our recently completed pharmacokinetics study which show the rate and extent of absorption of alprostadil
from a single dose of Alprox-TD(R) cream applied to the tip of the penis.
The published study entitled, "Topical Alprostadil
in the Treatment of Female Sexual Arousal Disorder" evaluated the efficacy and safety of three doses of Femprox(TM) cream in patients with FSAD.
The active ingredient in Topiglan -- alprostadil
-- differs from the active ingredient in Viagra and other Viagra-class investigational drugs in that it is delivered only to the penis, and appears to exert all of its effects there.
and foreign patent protection on SEPA-containing topical formulations of off-patent drugs such as minoxidil, a family of hormones, a group of non-steroidal anti-inflammatory drugs, anti-fungal agents and alprostadil
, the active ingredient in its Topiglan(R) product.
Nasdaq: NEXM) today announced additional clinical data relating to the study of the NexMed alprostadil
cream treatment for male erectile dysfunction ("ED"), conducted in China from December 1999 through April 2000.
Topiglan(TM) is a topical drug that contains SEPA(R) (Soft Enhancement of Percutaneous Absorption), and alprostadil
, a synthetic formulation of the natural prostaglandin E1 found in human semen.
MacroChem's patented excipient called SEPA(R) (Soft Enhancement of Percutaneous Absorption) enables alprostadil
to penetrate the penis.
Topiglan consists of a gel of 1% alprostadil
and SEPA(R), MacroChem's patented absorption-enhancing agent.
In this double-blind, placebo-controlled trial, approximately 230 women received treatment for a period of two months with alprostadil
at doses ranging from 200 to 800 micrograms or placebo.